Home Blog
The UK government will partner with four biopharma giants and the Wellcome Sanger Institute on a £200 million ($246.9 million) initiative to complete the whole genome sequencing of the 450,000 yet-to-be-sequenced participants in the UK Biobank. The public-private effort aims to improve public health through genetic research, as well as improve the prevention, diagnosis and treatment of a variety of...
Cardea's Genome Sensor
The CRISPR-Chip garnered much attention earlier this year when the novel graphene-based biosensor CRISPR-Cas technology was introduced in a Nature Biomedical Engineering publication in March. This week, the two companies that have been straddling the technology that is able to detect a specific genetic mutation from a sample without the need for amplification or sequencing announced that they have merged....
Results from a new study show the validity of using CSF as a medium for finding ctDNA to detect brain tumors. [Jonathan Bailey
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a gene that acts as a master regulator of schizophrenia during early human brain development, using computational tools designed to investigate gene transcription networks in large collections of brain tissues. The study represented one of the first successful examples of combining computational approaches and stem cell-based experimental models to unravel complex...
Biotechnology, conceptual illustration
Mayo Clinic and Google said they will jointly develop artificial intelligence (AI)-based diagnostics and carry out medical research using Google Cloud to store and secure the data, through a 10-year strategic partnership whose value was not disclosed. The partners said their collaboration is intended to advance healthcare by applying computing technologies that in addition to cloud computing and AI will...
Scientists at Cold Spring Harbor Laboratory (CSHL) say they have found a way to tackle the problem of drug resistance and stop the growth of pancreatic ductal adenocarcinoma (PDA) tumors in mice. Their findings (“Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer”) are published in the journal Clinical Cancer Research. Pancreatic cancer has a five-year...
Immune checkpoint protein molecule, illustration
A study published by Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), demonstrates that Personal Genome Diagnostics’ (PGDx) liquid biopsy technology can detect microsatellite instability (MSI) in circulating tumor DNA (ctDNA), and by doing so can estimate the likelihood of both an immediate and durable response to immune checkpoint blockade in cancer patients with MSI....
Prostate cancer cells, illustration
Precision medicine company Tempus, and antibody therapeutics company Genmab have announced a strategic collaboration that will leverage Tempus’ sequencing capabilities and platform of integrated clinical and molecular data with Genmab’s translational, biomarker and target discovery expertise. The companies will work together, based upon novel insights identified by Genmab, to advance new disease targets and biomarkers that may have the potential...
Tuberculosis bacteria, illustration
Scientists at the Rutgers New Jersey Medical School (NJMS) have found a genetically tractable cause of drug-tolerant tuberculosis (TB), which could pave the way for researchers to develop new drugs to combat the global TB epidemic and cure the disease. The study (“Phase variation in Mycobacterium tuberculosis glpK produces transiently heritable drug tolerance”), led by Hassan Safi, PhD, assistant...
Thermo Fisher Scientific said today it will develop a companion diagnostic for Eli Lilly’s Phase I/II cancer candidate LOXO-292 (selpercatinib) through a collaboration whose value was not disclosed. The companion diagnostic will use Thermo Fisher’s next-generation sequencing-based Oncomine Dx Target Test to identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with LOXO-292, which...
OpGen and Curetis said they will merge into a transatlantic diagnostics developer focused on molecular diagnostics and bioinformatics, with a pipeline of diagnostics specializing in infectious diseases and antimicrobial resistance (AMR). The combined company will market a commercial-stage diagnostics portfolio of CE-IVD-marked and FDA-cleared products and platforms, plus proprietary NGS-based and AI-powered technology designed to facilitate rapid molecular prediction of...
Scroll Up